Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at ...
Pyxis Oncology has concluded its first multi-target sublicensing agreement under the new arrangement with a stealth ADC company. This expansion builds on the former agreement, which provided Pyxis ...
Pyxis Oncology's antibody-drug conjugates (ADCs) and immuno-oncology (IO) programs employ novel and emerging strategies to target a broad range of solid tumors resistant to current standards of care.
It’s been a good week for investors of Pyxis Oncology (NASDAQ:PYXS), to say the least. Over the past 4 sessions Pyxis shares have gained 170%, bringing the year-to-date haul to a mighty 340%. This ...
Pyxis Oncology entered into definitive securities purchase agreements on June 30, 2026 for a private placement of 19,600,153 shares of common stock at $2.551 per share and accompanying warrants to buy ...
Pyxis Oncology Inc. company and executive profile by Barron's. View the latest PYXS company infomation and executive bios.
BOSTON--(BUSINESS WIRE)--Pyxis Oncology, an immuno-oncology company focused on developing a new family of antibody-based immunotherapies derived from novel insights into the biology of the tumor ...
While one might expect a positive readout from a biotech’s lead candidate to boost the company’s stock price, Pyxis Oncology’s shares—which have tumbled more than 40% this week—tell a different story.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results